|

Prognostic Value of BNP in MCS - a 25 Year Follow up Study

RECRUITINGSponsored by Rigshospitalet, Denmark
Actively Recruiting
SponsorRigshospitalet, Denmark
Started2020-09-18
Est. completion2045-08-01
Eligibility
Age18 Years+
View on ClinicalTrials.gov →

NCT04377854

Summary

A biobank has been created to investigate the prognostic value of biomarkers (mainly BNP) in patients implanted with durable mechanical assist devices comparing patients with advanced HF supported by MCS with those who are transplanted and those who remain on optimal medical therapy. Patients will be followed up for 25 years after inclusion.

Eligibility

Age: 18 Years+
Inclusion Criteria:

* All patients referred for evaluation for advanced HF treatment at the Rigshospital in Denmark
* Age\>18 years

Exclusion Criteria:

* No consent

Conditions5

Durable Mechanical Support DeviceHeart DiseaseHeart FailureLeft Ventricular Assist DevicePrognosis

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.